Streetbeat News

Stock Prices

WULF

TeraWulf Inc. (NASDAQ:WULF) shares are trading higher due to a rise in Bitcoin prices and a positive analyst rating from Cantor Fitzgerald. The stock has seen significant gains over the past year and month, but currently shows overbought conditions.

Portfolio Pulse from Erica Kollmann

June 12, 2024 | 3:42 pm

CVNA

Carvana shares are trading higher after the company announced the launch of same day delivery in Newark, New Jersey.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 3:42 pm

BTTR

BX

KKR

LLY

NVO

The success of weight loss drugs for humans, such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound, could potentially extend to the pet market. Companies like Okava Pharmaceuticals and Vivani Medical are developing weight loss drugs for pets, while Better Choice Company has acquired Aimia Pet Healthco to develop GLP-1 drugs. Despite skepticism from veterinary experts, the pet industry is projected to grow, and the introduction of such drugs could replicate the success seen in the human market.

Portfolio Pulse from Hayden Buckfire

June 12, 2024 | 3:42 pm

AFRM

Affirm Holdings shares are trading higher following the announcement of a partnership with Brittain Resorts & Hotels.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 3:39 pm

DDC

DayDayCook shares are trading higher following the announcement of its acquisition of Omsom.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 3:36 pm

LGVN

Longeveron shares are trading higher following the circulation of a Zacks Small Cap Research report that values the company at $15.10 per share.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 3:35 pm

VKTX

Deep-pocketed investors have shown unusual bearish options activity for Viking Therapeutics (NASDAQ:VKTX), with 66% of the trades being bearish. This significant move suggests potential upcoming volatility for VKTX. The stock is currently trading at $53.48, up by 1.42%, with the next earnings report due in 42 days.

Portfolio Pulse from Benzinga Insights

June 12, 2024 | 3:32 pm

SNOW

Deep-pocketed investors are showing significant interest in Snowflake (NYSE:SNOW) with a notable amount of options activity. The sentiment among these investors is mixed, with 48% bullish and 24% bearish. Analysts have varied ratings on the stock, with target prices ranging from $190 to $240.

Portfolio Pulse from Benzinga Insights

June 12, 2024 | 3:31 pm

BIIB

LLY

At the Goldman Sachs Conference, a Biogen executive stated that the Alzheimer's drug market will develop faster with Eli Lilly's involvement. However, the executive refrained from speculating on the future of Donanemab's label.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 3:30 pm

BIIB

LLY

Biogen's executive expressed confidence in the success of their Alzheimer's drug, LEQEMBI, regardless of competition. The executive also mentioned that Eli Lilly's experimental Alzheimer's drug will help grow the market. This was stated at the Goldman Sachs Conference.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 3:28 pm